$5.16 Million in Sales Expected for Alliqua Biomedical Inc (ALQA) This Quarter
Analysts expect that Alliqua Biomedical Inc (NASDAQ:ALQA) will report sales of $5.16 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Alliqua Biomedical’s earnings. The highest sales estimate is $5.50 million and the lowest is $4.83 million. Alliqua Biomedical reported sales of $4.94 million during the same quarter last year, which indicates a positive year-over-year growth rate of 4.5%. The firm is scheduled to announce its next earnings report on Tuesday, March 6th.
On average, analysts expect that Alliqua Biomedical will report full year sales of $5.16 million for the current fiscal year. For the next fiscal year, analysts anticipate that the business will post sales of $23.38 million per share, with estimates ranging from $22.46 million to $24.30 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Alliqua Biomedical.
Several research firms recently commented on ALQA. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Alliqua Biomedical in a research note on Monday, September 18th. Zacks Investment Research raised shares of Alliqua Biomedical from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research note on Tuesday, September 12th. Finally, ValuEngine upgraded shares of Alliqua Biomedical from a “sell” rating to a “hold” rating in a research report on Friday, October 6th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $11.25.
Shares of Alliqua Biomedical (NASDAQ ALQA) opened at $2.13 on Tuesday. Alliqua Biomedical has a one year low of $1.99 and a one year high of $8.50.
Alliqua Biomedical Company Profile
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alliqua Biomedical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical Inc and related companies with MarketBeat.com's FREE daily email newsletter.